Vivozon Pharmaceutical Dirección

Dirección controles de criterios 0/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Jin Lee

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	n/a
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	sin datos

Actualizaciones recientes de la dirección

Recent updates

Did You Miss Vivozon Healthcare's (KOSDAQ:082800) Impressive 116% Share Price Gain?

Dec 04

CEO

Jin Lee

no data

Permanencia

Mr. Jin Soo Lee serves as the Chief Executive Officer of Vivozon Pharmaceutical Co., Ltd. (formerly known as Vivozon Healthcare, Inc.) (formerly known as Lumimicro Co., Ltd).

Vivozon Pharmaceutical Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

No independent directors

No independent directors

No independent directors

Recent updates

New minor risk - Market cap size

We Think Vivozon Pharmaceutical (KOSDAQ:082800) Has A Fair Chunk Of Debt

No independent directors

Vivozon Pharmaceutical Co., Ltd. (KOSDAQ:A082800) announces an Equity Buyback for KRW 5 million worth of its shares.

Vivozon Pharmaceutical Co., Ltd. (KOSDAQ:A082800) announces an Equity Buyback for KRW 5 million worth of its shares.

Full year 2022 earnings released: ₩177 loss per share (vs ₩426 loss in FY 2021)

Vivozon Pharmaceutical Co., Ltd. announced that it expects to receive KRW 2.000000072 billion in funding

Vivozon Pharmaceutical Co., Ltd. announced that it has received KRW 6 billion in funding

No independent directors

No independent directors

Vivozon Healthcare, Inc. announced that it has received KRW 58.171164251 billion in funding from Vaultea, Inc. and other investors

Vivozon Healthcare, Inc. announced that it expects to receive KRW 10 billion in funding from Korea Fixed Income Investment Advisory Co., Ltd.

Is Vivozon Healthcare (KOSDAQ:082800) A Risky Investment?

Full year 2020 earnings released: ₩334 loss per share (vs ₩213 loss in FY 2019)

New 90-day low: ₩1,780

Estimating The Intrinsic Value Of Vivozon Healthcare, Inc. (KOSDAQ:082800)

New 90-day low: ₩1,955

Did You Miss Vivozon Healthcare's (KOSDAQ:082800) Impressive 116% Share Price Gain?

New 90-day high: ₩2,435

Lumimicro Co., Ltd (KOSDAQ:A082800) agreed to acquire 85.78% stake in Inist Bio Co.,Ltd. from Inistpharm Co.,Ltd, Kim, Kook-Hyun, Park, Ji-seop and others for KRW 60.9 billion.

New 90-day low - ₩1,305

CEO

Permanencia